Scilex sets $25/month cap on out-of-pocket costs for select non-opioid products for commercially insured patients.
Scilex Holding Company, specializing in non-opioid pain management products, announces a $25/month cap on out-of-pocket costs for its product portfolio for commercially insured patients, with some eligible patients paying $0. This applies to ZTlido® (postherpetic neuralgia), ELYXYB® (migraine), and Gloperba® (gout flare prophylaxis, launching 1H 2024). The company invests in co-pay programs to enhance affordability and access.
March 21, 2024
4 Articles